Literature DB >> 12432942

Prostanoid receptor subtypes.

Kazuhito Tsuboi1, Yukihiko Sugimoto, Atsushi Ichikawa.   

Abstract

Prostanoids are a group of lipid mediators that include the prostaglandins (PG) and thromboxanes (TX). Upon cell stimulation, prostanoids are synthesized from arachidonic acid via the cyclooxygenase (COX) pathway and released outside the cells to exert various physiological and pathological actions in a variety of tissues and cells. The activities of prostanoids are mediated by specific G protein-coupled receptors, which have been classified on the basis of pharmacological experiments into eight types and subtypes according to their responsiveness to selective agonists and antagonists. These prostanoid receptors have been cloned from various species including human, and their distinct binding properties and signal transduction pathways have been characterized by analyses of cells expressing each receptor. Furthermore, the distribution patterns of prostanoid receptor mRNAs have been determined in tissues and cells for various species. This information is useful for understanding the molecular basis of the pathophysiological actions of prostanoids.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12432942     DOI: 10.1016/s0090-6980(02)00054-0

Source DB:  PubMed          Journal:  Prostaglandins Other Lipid Mediat        ISSN: 1098-8823            Impact factor:   3.072


  35 in total

Review 1.  Vasoconstrictor prostanoids.

Authors:  Michel Félétou; Yu Huang; Paul M Vanhoutte
Journal:  Pflugers Arch       Date:  2010-03-24       Impact factor: 3.657

2.  Arachidonic acid induces production of 17,20β-dihydroxy-4-pregnen-3-one (DHP) via a putative PGE2 receptor in fish follicles from the Eurasian perch.

Authors:  E Henrotte; S Milla; S N M Mandiki; P Kestemont
Journal:  Lipids       Date:  2010-12-24       Impact factor: 1.880

3.  Regulation of Wnt/beta-catenin pathway by cPLA2alpha and PPARdelta.

Authors:  Chang Han; Kyu Lim; Lihong Xu; Guiying Li; Tong Wu
Journal:  J Cell Biochem       Date:  2008-10-01       Impact factor: 4.429

4.  Anandamide-derived prostamide F2α negatively regulates adipogenesis.

Authors:  Cristoforo Silvestri; Andrea Martella; Neil J Poloso; Fabiana Piscitelli; Raffaele Capasso; Angelo Izzo; David F Woodward; Vincenzo Di Marzo
Journal:  J Biol Chem       Date:  2013-06-25       Impact factor: 5.157

Review 5.  A Review of Prostanoid Receptors: Expression, Characterization, Regulation, and Mechanism of Action.

Authors:  Roger G Biringer
Journal:  J Cell Commun Signal       Date:  2020-09-24       Impact factor: 5.782

6.  Pharmacology.

Authors:  Hayrunnisa Bolay; Paul Durham
Journal:  Handb Clin Neurol       Date:  2010

7.  In vitro study of antiadipogenic profile of latanoprost, travoprost, bimatoprost, and tafluprost in human orbital preadiopocytes.

Authors:  Hee Young Choi; Ji Eun Lee; Ji Woong Lee; Hyun Jun Park; Ji Eun Lee; Jae Ho Jung
Journal:  J Ocul Pharmacol Ther       Date:  2011-11-22       Impact factor: 2.671

8.  Antihypertensive effects of selective prostaglandin E2 receptor subtype 1 targeting.

Authors:  Youfei Guan; Yahua Zhang; Jing Wu; Zhonghua Qi; Guangrui Yang; Dou Dou; Yuansheng Gao; Lihong Chen; Xiaoyan Zhang; Linda S Davis; Mingfeng Wei; Xuefeng Fan; Monica Carmosino; Chuanming Hao; John D Imig; Richard M Breyer; Matthew D Breyer
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

9.  ONO-54918-07, a stable prostacyclin analogue, mimics the effect of prostaglandin PGE1 on NG108-15 cells.

Authors:  Adolfo Cavalié; Stephan Ernst Philipp; Hans Meves
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-10-19       Impact factor: 3.000

10.  Genetic deletion or pharmacological inhibition of cyclooxygenase-1 attenuate lipopolysaccharide-induced inflammatory response and brain injury.

Authors:  Sang-Ho Choi; Robert Langenbach; Francesca Bosetti
Journal:  FASEB J       Date:  2007-12-27       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.